Philogen stock
Price history
−10.85% over the period1 year: from €23.50 (November 20, 2025) to €20.95 (November 20, 2026), −10.85%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | €20.95 |
| October 30, 2026 | €20.70 |
| September 30, 2026 | €22.50 |
| August 31, 2026 | €23.05 |
| July 31, 2026 | €23.80 |
| June 30, 2026 | €23.20 |
| May 29, 2026 | €23.25 |
| April 30, 2026 | €21.65 |
| March 31, 2026 | €22.70 |
| February 27, 2026 | €21.00 |
| January 30, 2026 | €21.00 |
| December 30, 2025 | €23.30 |
| November 28, 2025 | €24.10 |
| November 20, 2025 | €23.50 |
At a glance
The company
Biotechnology company developing drugs for oncology and chronic inflammatory diseases
Latest results
Quarter to June 30, 2026 · EPS -€0.49
TickerLandia's take on Philogen
- Cheaper than similar companies: trailing 12-month P/E 3.7 vs 15 (−75%) in a group of 7.
- Strong point: Profitability (90/100 in its group). Weak point: Market momentum (34/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−19.42% from the 52-week high
Analysts · 3 analysts
Average target€28.33+35.24% vs. price
Buy 2 · Hold 1 · Sell 0
TickerLandia Fingerprint: Philogen
Compared with similar companies: very low price and very high profitability.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricevery low7
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 2.05 1 Price/sales 2.61 8 P/E (trailing 12 months) 3.67 4 Price/book 2.49 16 Profitabilityvery high90
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 87.2% 66 Operating margin 79.1% 99 Net margin 71.4% 96 ROE 98.4% 89 ROA 56.2% 99 Earnings stabilitylow37
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 167.5% 30 Loss-making yearscounts in reverse: lower means more earnings stability 3 of 5 annual reports 43 Growthaverage53
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +128.10% 87 Earnings growth (year over year) +31.83% 65 Revenue growth (year over year) −52.30% 6 Financial strengthhigh77
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.45 57 Interest coverage 776.3 99 Current ratio 6.99 81 Debt/equitycounts in reverse: lower means more financial strength 0.03 73 Dividendaverage51
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 1 year 30 Dividend yield 3.4% 97 Payout ratio 12.5% 25 Market momentumweak34
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −3.80% 38 Relative strength (6 months) −4.70% 45 1-year return −10.85% 21 Distance from 200-day average −6.59% 33 Risklow26
How much the price swings.
Metric Value Position in group Volatility (60 days) 23.6% 34 Beta (1 year) 0.23 9 Maximum drawdown (12 months) 20.5% 35
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Philogen is cheaper than similar companies
Philogen's P/E (trailing 12 months): 3.67, −75% against the median of a group of 7 similar companies (14.7).
Compared with 7 similar companies
| Metric | Philogen | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 3.67 | Low | |
| Operating margin | 79.1% | High | |
| ROE | 98.4% | High | |
| Debt/equity | 0.03 | Middle | |
| Price/book | 2.49 | Low |
Grey band: the middle half of the group; tick: the median; dot: Philogen. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€4.07M
Latest quarter · Q2 2026
Net income
-€19.59M
Latest quarter · Q2 2026
Quarterly net margin
-482.0%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €824.35M
- P/E
- 3.7
- EPS
- €5.58
- Volume
- 27.13K
- Daily trading
- €285.89K
- Dividend yield
- 3.34%
- Last ex-dividend on May 18, 2026
How Philogen is changing
All resultsRevenue grew 119.0% a year on average over the last 5 years
Operating margin rose from −0.5% to 80.4%
Profits turn into cash: free cash flow equal to 109% of net income
Returns
Philogen returns with dividends
€1,000 invested in Philogen 5 years ago, on November 22, 2021, would be worth €1,425 today: +42.52% in total, +7.35% per year. This is the price return only: dividends are excluded.
| Period | Philogen | FTSE MIB | €1,000 becomes |
|---|---|---|---|
| 1 month | −3.23% | −0.75% | €968 |
| 6 months | −5.63% | −0.97% | €944 |
| Year to date | −10.09% | +8.36% | €899 |
| 1 year | −8.03% | +13.48% | €920 |
| 3 years | +16.39% | +64.86% | €1,164 |
| 5 years | +42.52% | +77.86% | €1,425 |
Over the last 6 months it has done better than 15% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. FTSE MIB: price only. Calculate your investment
The chart in detail
Philogen: technical analysis
Philogen is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 23.5% below its all-time closing high (€27.40, June 12, 2025).
- Trend
- Downward
- RSI (14 sessions)
- 47
- Between 30 and 70
- vs 200-session average
- −6.59%
Active signals
The price is moving in an unusually narrow range compared with the last year.
since November 17, 2026
Trading on November 20, 2026 was 2.5 times the 20-session average.
since November 18, 2026
Support and resistance
Price areas where Philogen has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€22.68+8.26%5 touches, last on September 15, 2026
- Resistance€22.16+5.80%7 touches, last on October 27, 2026
- Resistance€21.54+2.82%6 touches, last on November 10, 2026
- Last price€20.95
- Support€20.87−0.40%3 touches, last on October 20, 2026
- Support€20.45−2.39%3 touches, last on November 3, 2026
Volatility and risk
Over the last year it has moved little with the FTSE MIB.
- Beta (1 year) vs FTSE MIB
- 0.23
- Volatility (60 sessions, annualised)
- 23.6%
- Largest fall in the last year
- −20.54%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Philogen: seasonality
Average monthly price change over 6 years
Over the last 6 years, the strongest month for Philogen has been May: +5.55% on average, positive in 5 years out of 6. The weakest has been January: −4.51% on average, positive in 1 years out of 5. November, the current month, has been positive in 2 years out of 5 (+0.29% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −4.51% | −7.84% | 1 of 5 |
| February | +2.89% | +1.68% | 3 of 5 |
| March | +2.03% | +3.23% | 3 of 5 |
| April | +0.61% | +0.50% | 3 of 6 |
| May | +5.55% | +3.75% | 5 of 6 |
| June | −2.00% | −2.94% | 1 of 6 |
| July | +2.60% | +3.33% | 5 of 6 |
| August | +1.54% | +1.49% | 4 of 6 |
| September | −3.72% | −4.27% | 2 of 6 |
| October | +1.23% | +2.61% | 4 of 6 |
| November | +0.29% | −1.85% | 2 of 5 |
| December | +0.18% | +0.82% | 3 of 5 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Philogen and its competitors
Philogen reported revenue of 319.7 million euros in the fiscal year ended 31 December 2025, and its work centres on drugs for cancer and chronic inflammatory conditions. Nidlegy is in Phase III testing for advanced melanoma and Fibromun in Phase III for soft-tissue sarcoma, while Darleukin, Dekavil and Dodekin are in earlier-stage trials for lung cancer, chronic inflammatory disorders and various solid tumors. A second line of small molecules, including OncoFAP, OncoACP3 and OncoCAIX, targets solid tumors, prostate cancer and renal cell carcinoma. The company operates in Italy, Switzerland, the United States and the European Union.
- Headquarters
- Sovicille, Italy
- Employees
- 230
- Founded
- 1996
- Chief executive
- Dario Neri
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| PhilogenPHIL | $905.96M | 79.1% | 3.67 | −5.63% |
| InventivaIVA | $890.8M | -5,980.9% | — | −33.75% |
| Pharming GroupPHARM | $841.25M | 12.8% | 36.1 | −2.57% |
| Basilea PharmaceuticaBSLN | $1.07B | 24.2% | 18.1 | +35.06% |
| Pharma MarPHM | $1.1B | 21.3% | 14.7 | −41.56% |
| GubraGUBRA | $730.02M | -73.1% | — | −22.24% |
Same industry or related industries, similar size. Compare Philogen with its competitors · Full profile
